University Hospitals Selects GenomOncology's GO Clinical Workbench to Launch their first NGS-based Cancer Diagnostic Test

News provided by

Oct 27, 2014, 07:00 ET

CLEVELAND, Oct. 27, 2014 /PRNewswire/ -- GenomOncology today announced that University Hospitals (UH) Case Medical Center and UH Seidman Cancer Center (Cleveland, Ohio) have selected the company's GO Clinical Workbench^TM to launch a clinical cancer product. UH will leverage the GO Clinical Workbench for workflow management from raw sequencing data through delivery of an actionable clinical report for oncologists.

UH, the second largest employer in Northeast Ohio with 25,000 employees, serves the needs of patients through an integrated network of 15 hospitals, 26 outpatient centers and primary care physician offices in 15 counties. Its main campus includes UH Case Medical Center, UH Rainbow Babies & Children's Hospital, UH MacDonald Women's Hospital, and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University.

"Cancer research not only advances cancer treatment, it also provides a source of hope and help to patients for whom other treatments have failed," said Joseph Willis, MD, Division Chief, Clinical Pathology at UH Case Medical Center. "Coupling our research efforts with the powerful analytics provided by the GO Clinical Workbench will allow us to quickly translate scientific findings into the highest quality patient care."

GenomOncology's GO Clinical Workbench streamlines the use of Next Generation Sequencing (NGS) data and allows molecular pathology laboratories to produce an actionable clinical report using the molecular profile of an individual patient's tumor. The platform is configured to each clinical laboratory's specific needs with systems integration (LIMS, EMR, etc.), setting of quality control and annotation parameters, and design of the resultant clinical report.

"GenomOncology is honored to have our GO Clinical Workbench selected by University Hospitals, one of the nation's leading health care systems," said Manuel Glynias, President and CEO of GenomOncology. "We are confident that our robust technology platform and onsite support will allow University Hospitals to continue to provide the most advanced care to their patients."

About University Hospitals

University Hospitals, the second largest employer in Northeast Ohio with 25,000 employees, serves the needs of patients through an integrated network of 15 hospitals, 28 outpatient health centers and primary care physician offices in 15 counties. At the core of our $3.5 billion health system is University Hospitals Case Medical Center, ranked among America's 50 best hospitals by U.S. News & World Report in all 12 methodology-ranked specialties. The primary affiliate of Case Western Reserve University School of Medicine, UH Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and genetics. Its main campus includes UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University. For more information, go to www.uhhospitals.org

About GenomOncology

GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench^TM, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient's tumor genome into an actionable clinical report. GenomOncology's research platform, GenomAnalytics^TM, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company's website at www.genomoncology.com.

For more information regarding this announcement, please contact:

Jane Krug, PR Contact
Phone: 504-390-5935
Email: [email protected]

Logo - http://photos.prnewswire.com/prnh/20140204/CL58248LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-hospitals-selects-genomoncologys-go-clinical-workbench-to-launch-their-first-ngs-based-cancer-diagnostic-test-884612915.html

SOURCE GenomOncology